On August 13, HANSOH PHARMA rose 3.94% in regular trading, trading at HK$34.76/share, with turnover of HK$153 million.

The pharmaceutical sector saw a broad rebound on the day, with CSPC Pharma up 5.82%, CF Pharmtech up 5.28%, and Hengrui Pharma up 1.34%. On the news front, multiple catalysts have converged for the company. CLSA maintained its Outperform rating and raised its target price to HK$42, projecting five new drugs to receive approval next year, including its B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors. CLSA forecasts revenue growth of 14%, 10%, and 14% for the coming three years, with net profit growth of 9%, 12%, and 16% respectively.

The company recently announced its proprietary ADC HS-20093 met primary endpoints in Phase III trials for both osteosarcoma and small cell lung cancer, and new drug HS-10582 received clinical trial approval for hypercholesterolemia. Interim results are scheduled for disclosure on August 26, with market expectations for earnings delivery rising.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)